Michael D. Prados MD, FACP

tl_files/NS_Main/Faculty/prados.jpg

Professor in Residence of Neurological Surgery, Charles B. Wilson MD Endowed Chair

Director of Translational Research in Neuro-Oncology

Principal Investigator, Pediatric Brain Tumor Consortium

Principal Investigator, Brain Tumor Research Center


Director of the Department's Translational Research Program, Dr. Prados has over 20 years' experience at UCSF in treating and supervising the treatment of both adults and children who have brain tumors. The National Cancer Institute's Adult Brain Tumor Consortium, which sponsors trials of treatment regimens for brain tumors, is based at UCSF under Dr. Prados' leadership, and he is principal investigator of the Pediatric Brain Tumor Consortium site at UCSF, which is one of 7 institutions in the United States selected to participate in this NIH-funded cooperative effort to develop effective new strategies for treating children with malignant brain tumors.

Dr. Prados, both individually and in conjunction with multi-center and multidisciplinary clinical research efforts, supervises and participates in conducting extensive trials of clinical therapy for malignant brain tumors. He is the supervising preceptor training BTRC clinical fellows in conducting clinical trials and analyzing and interpreting clinical trial data. His research interest is in clinical research trials for primary brain tumors. Dr. Prados has been a principal investigator, co-investigator, or collaborating investigator in over 35 research protocols from the National Institutes of Health (NIH), UCSF, and Industry studies over the last several years, and currently is principal investigator or co-investigator of 4 active NIH grants.

Education, Training, and Previous Positions

1970: BS, University of New Orleans
1974; MD, Louisiana State University (LSU) School of Medicine
1974-1975: Internship in Medicine, Charity Hospital in New Orleans
1975-1977: Residency in Internal Medicine, LSU Earl K Long Hospital
1977-1978: Instructor, Internal Medicine, LSU School of Medicine
1979-1982: Assistant Professor, Internal Medicine, LSU School of Medicine
1983: Fellowship in Pulmonary Medicine, Tulane School of Medicine
1984-1985: Assistant Clinical Director of Pulmonary Medicine, Touro Hospital, Tulane University School of Medicine
1985-1987: Fellowship in Neuro-Oncology, University of California San Francisco
1985-1987: Clinical Instructor of Neurosurgery/Neuro-Oncology, Department of Neurological Surgery, UCSF
1987-1989: Acting Director of the UCSF Neuro-Oncology Service
1988-1991: Assistant Clinical Professor, Department of Neurological Surgery, UCSF
1989-2003: Director of the UCSF Neuro-Oncology Service
1991-1995: Associate Professor in Residence Neurological Surgery, UCSF
1995-present: Professor in Residence, Neurological Surgery, UCSF
2003-Present: Director of Translational Research, Neurological Surgery, UCSF

Selected Professional Memberships and Appointments

American College of Physicians
American Society of Clinical Oncology
Children's Oncology Group
Associate editor, editorial reviewer: Journal of Neuro-Oncology
Associate editor, editorial reviewer: Neuro-Oncology

Selected Honors and Awards

1976-1977: Chief Resident, Internal Medicine, LSU, E.K. Long Hospital
1985-1987: Clinical Fellow, American Cancer Society
1997: Clinical Excellence Award, Society of Neuro-Oncology
1995-1997: Vice President, Society of Neuro-Oncology
2004-2006: President, Society of Neuro-Oncology
2014: Victor Levin Award for Neuro-Oncology Research, Society of Neuro-Oncology

Selected Recent Publications

1: Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug;62 Suppl 1:160-5. doi: 10.1227/NEU.0000000000000801. PubMed PMID: 26181937.

2: Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Jul 13. pii: JCO.2014.60.1591. [Epub ahead of print] PubMed PMID: 26169613.

3: Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10. PubMed PMID: 26061753; PubMed Central PMCID: PMC4489704.

4: Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review. PubMed PMID: 25934816; PubMed Central PMCID: PMC4490873.

5: Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug;77(2):248-53. doi: 10.1227/NEU.0000000000000766. PubMed PMID: 25856113; PubMed Central PMCID: PMC4506198.

6: Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct;16 Suppl 7:vii36-47. doi: 10.1093/neuonc/nou226. PubMed PMID: 25313237; PubMed Central PMCID: PMC4195530.

7: Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan;121(1):135-40. doi: 10.1007/s11060-014-1611-2. Epub 2014 Sep 11. PubMed PMID: 25208478.

8: Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb;17(2):180-8. doi: 10.1093/neuonc/nou154. Epub 2014 Aug 26. PubMed PMID: 25165194; PubMed Central PMCID: PMC4288520.

9: Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, Pico AR, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, O'Neill BP, Sicotte H, Eckel-Passow JE; ENGAGE Consortium Telomere Group, van der Harst P, Wiencke JK, Samani NJ, Jenkins RB, Wrensch MR. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet. 2014 Jul;46(7):731-5. doi: 10.1038/ng.3004. Epub 2014 Jun 8. PubMed PMID: 24908248; PubMed Central PMCID: PMC4074274.

10: Prados MD. Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure". Neuro Oncol. 2014 May;16(5):617-8. doi: 10.1093/neuonc/nou050. Epub 2014 Apr 8. PubMed PMID: 24714524; PubMed Central PMCID: PMC3984566.

11: Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, Corcoran A, Jones DT, Sturm D, Johann P, Tomita T, Goldman S, Nagib M, Bendel A, Goumnerova L, Bowers DC, Leonard JR, Rubin JB, Alden T, Browd S, Geyer JR, Leary S, Jallo G, Cohen K, Gupta N, Prados MD, Carret AS, Ellezam B, Crevier L, Klekner A, Bognar L, Hauser P, Garami M, Myseros J, Dong Z, Siegel PM, Malkin H, Ligon AH, Albrecht S, Pfister SM, Ligon KL, Majewski J, Jabado N, Kieran MW. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014 May;46(5):462-6. doi: 10.1038/ng.2950. Epub 2014 Apr 6. PubMed PMID: 24705250; PubMed Central PMCID: PMC4282994.

12: Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep;16(9):1255-62. doi: 10.1093/neuonc/nou044. Epub 2014 Mar 26. PubMed PMID: 24670608; PubMed Central PMCID: PMC4136897.

13: Prados MD. "We will know it when we see it;" bevacizumab and glioblastoma. Neuro Oncol. 2014 Apr;16(4):469-70. doi: 10.1093/neuonc/nou036. PubMed PMID: 24637548; PubMed Central PMCID: PMC3956364.

14: Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul;16(7):984-90. PubMed PMID: 24637230; PubMed Central PMCID: PMC4057142.

15: Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26. PubMed PMID: 24470557; PubMed Central PMCID: PMC3956354.

16: Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan;16(2):274-9. doi: 10.1093/neuonc/not203. Epub 2013 Dec 12. PubMed PMID: 24335700; PubMed Central PMCID: PMC3895386.

17: Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov I, Tom MW, Prados MD, James CD, Berger MS, Gupta N, Haas-Kogan DA. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro Oncol. 2014 Mar;16(3):352-60. doi: 10.1093/neuonc/not220. Epub 2013 Dec 4. PubMed PMID: 24305702; PubMed Central PMCID: PMC3922515.

18: Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, Zheng S, McCoy LS, Bracci PM, Anderson E, Hsuang G, Wiemels JL, Pico AR, Smirnov I, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, Sicotte H, Eckel-Passow JE, Wiencke JK, Jenkins RB, Wrensch MR. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro Oncol. 2013 Aug;15(8):1041-7. doi: 10.1093/neuonc/not051. Epub 2013 Jun 3. PubMed PMID: 23733245; PubMed Central PMCID: PMC3714154.

19: Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S, Wen PY, Pollack IF, Zurakowski D, Kun LE, Prados MD, Rutkowski S, Kieran MW. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013 Sep;60(9):1397-401. doi: 10.1002/pbc.24562. Epub 2013 Apr 26. PubMed PMID: 23625747.

20: Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD; Collaborative Ependymoma Research Network. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol. 2013 Sep;23(5):584-94. doi: 10.1111/bpa.12050. Epub 2013 Mar 28. PubMed PMID: 23452038.

21: Dolores Arenas M, Pérez-García R, Bennouna M, Blanco A, Mauricio O, Prados MD, Lerma JL, Luisa Muñiz M, Belén Martín M; Estudio COMQUELFOS. Improvement of therapeutic compliance in haemodialysis patients with poor phosphorus control and adherence to treatment with binders: COMQUELFOS study. Nefrologia. 2013;33(2):196-203. doi: 10.3265/Nefrologia.pre2012.Oct.11726. Epub 2013 Jan 6. English, Spanish. PubMed PMID: 23364580.

22: Rice T, Zheng S, Decker PA, Walsh KM, Bracci P, Xiao Y, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Hsuang G, Wiemels JL, Tihan T, Pico AR, Prados MD, Chang SM, Berger MS, Caron A, Fink S, Kollmeyer T, Rynearson A, Voss J, Kosel ML, Fridley BL, Lachance DH, Eckel-Passow JE, Sicotte H, O'Neill BP, Giannini C, Wiencke JK, Jenkins RB, Wrensch MR. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro Oncol. 2013 May;15(5):535-41. doi: 10.1093/neuonc/nos324. Epub 2013 Jan 29. PubMed PMID: 23361564; PubMed Central PMCID: PMC3635511.

23: Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013 Feb;15(2):189-97. doi: 10.1093/neuonc/nos305. Epub 2012 Dec 21. PubMed PMID: 23262509; PubMed Central PMCID: PMC3548589.

24: Hiniker A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, Perry A. Gliosarcoma arising from an oligodendroglioma (oligosarcoma). Clin Neuropathol. 2013 May-Jun;32(3):165-70. doi: 10.5414/NP300577. PubMed PMID: 23254140.

25: Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24. PubMed PMID: 23099651; PubMed Central PMCID: PMC3499017.

26: Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 1;18(21):6032-9. doi: 10.1158/1078-0432.CCR-12-1841. Epub 2012 Aug 24. PubMed PMID: 22923449; PubMed Central PMCID: PMC3947570.

27: Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013 Jan 1;19(1):205-14. doi: 10.1158/1078-0432.CCR-11-3358. Epub 2012 Aug 7. PubMed PMID: 22872572.

28: Jenkins RB, Xiao Y, Sicotte H, Decker PA, Kollmeyer TM, Hansen HM, Kosel ML, Zheng S, Walsh KM, Rice T, Bracci P, McCoy LS, Smirnov I, Patoka JS, Hsuang G, Wiemels JL, Tihan T, Pico AR, Prados MD, Chang SM, Berger MS, Caron AA, Fink SR, Halder C, Rynearson AL, Fridley BL, Buckner JC, O'Neill BP, Giannini C, Lachance DH, Wiencke JK, Eckel-Passow JE, Wrensch MR. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet. 2012 Oct;44(10):1122-5. doi: 10.1038/ng.2388. Epub 2012 Aug 26. PubMed PMID: 22922872; PubMed Central PMCID: PMC3600846.

29: Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD, Weiss WA, Berger MS, Gupta N, Haas-Kogan DA. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol. 2012 Sep;14(9):1146-52. doi: 10.1093/neuonc/nos140. Epub 2012 Jun 29. PubMed PMID: 22753230; PubMed Central PMCID: PMC3424210.

30: Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31. PubMed PMID: 22588883; PubMed Central PMCID: PMC3354723.

31: Xiao Y, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Wiemels JL, Tihan T, Prados MD, Chang SM, Berger MS, Kosel ML, Fridley BL, Lachance DH, O'Neill BP, Buckner JC, Thompson RC, Nabors LB, Olson JJ, Brem S, Madden MH, Browning JE, Wiencke JK, Egan KM, Jenkins RB, Wrensch MR. SSBP2 variants are associated with survival in glioblastoma patients. Clin Cancer Res. 2012 Jun 1;18(11):3154-62. doi: 10.1158/1078-0432.CCR-11-2778. Epub 2012 Apr 3. PubMed PMID: 22472174; PubMed Central PMCID: PMC3607457.

32: Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012 Jun;69(6):1507-18. doi: 10.1007/s00280-012-1854-6. Epub 2012 Mar 7. PubMed PMID: 22392572; PubMed Central PMCID: PMC4351868.

33: Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011 Dec 1;29(34):4482-90. doi: 10.1200/JCO.2010.33.8715. Epub 2011 Oct 24. PubMed PMID: 22025148; PubMed Central PMCID: PMC3236649.

34: Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec;13(12):1331-8. doi: 10.1093/neuonc/nor130. Epub 2011 Sep 6. PubMed PMID: 21896554; PubMed Central PMCID: PMC3223090.

35: Pejavar S, Polley MY, Rosenberg-Wohl S, Chennupati S, Prados MD, Berger MS, Banerjee A, Gupta N, Haas-Kogan D. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012 Jan;106(2):367-75. doi: 10.1007/s11060-011-0671-9. Epub 2011 Aug 9. PubMed PMID: 21826561.

36: Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb;70(2):361-70. doi: 10.1227/NEU.0b013e3182314f9d. PubMed PMID: 21841523.

37: Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol. 2011 Dec;13(12):1288-95. doi: 10.1093/neuonc/nor139. Epub 2011 Sep 27. PubMed PMID: 21954443; PubMed Central PMCID: PMC3223095.